Pharma companies should review their commission-based compensation arrangements with independent contractors to address enforcement risk under the Anti-Kickback Statute, in light of recent Department of Justice enforcement.
Jaime L.M. Jones
Advertisement
Partner, Sidley Austin LLP
Articles by Jaime L.M. Jones
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
Eli Lilly to Submit Oral GLP-1 for FDA Priority Review Program: Report
2
GCC Emerges as a New Strategic Anchor for Global Venture Capital
3
Tylenol Maker Sued While Kennedy Says No ‘Sufficient’ Evidence for Autism Link
4
Pharmaceutical Executive Daily: Novo Nordisk's Unsolicited Acquisition Proposal
5
